Introduction: Overactive bladder syndrome (OAB) is a subset of storage LUTS (lower urinary tract symptoms) highly prevalent in diabetes, obesity and hypertension. Benign prostatic hyperplasia (BPH) in aging men is another pathological condition highly associated with OAB secondary to bladder outlet obstruction (BOO). The β3-adrenoceptor apparently is the major receptor to induce bladder relaxations. Mirabegron is the first β3-adrenoceptor (β3-AR) agonist approved for OAB treatment (1). Urethral smooth muscle plays a critical role to urinary continence, but no studies have examined the mirabegron-induced urethral relaxations. This study was designed to investigate the mirabegron-induced mouse urethral relaxations. In preliminary assays, mirabegron showed an unexpected action by competitively antagonizing the urethral contractions induced by the α1-AR agonist phenylephrine. Therefore, this study also aimed to characterize the α1-AR blockade by mirabegron, focusing on the α1-AR subtypes in rat vas deferens and prostate (α1A-AR), spleen (α1B-AR) and aorta (α1D-AR) preparations.
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Methods: Functional assays were carried out in mouse urethra rings, and rat vas deferens, prostate, aorta and spleen. β3-AR expression (mRNA and immunohistochemistry) and cyclic AMP levels were determined in mouse urethra. Competition assays for the specific binding of [3H]Prazosin to membrane preparations of HEK 293 cells expressing each of the human α1-ARs subtypes were performed.
Results: Mirabegron (1 nM-100 µM) produced concentration-dependent urethral relaxations that were right shifted by the selective β3-AR antagonist L 748,337, but unaffected by β1-and β2-AR antagonists (atenolol and ICI 118,551, respectively). The non-selective β-AR agonist isoprenaline produced biphasic relaxant responses that were turned into a monophasic concentration-response curve in presence of L 748,337. Mirabegron-induced relaxations were enhanced by the phosphodiesterase-4 inhibitor rolipram, and associated with β3-ARstimulated cAMP synthesis. Mirabegron (1 to 100 µM) also produced rightward displacements in urethral contractions induced by phenylephrine. Schild regression analysis revealed that mirabegron behaves as a competitive antagonist of α1-AR in urethra, vas deferens and prostate (α1A-AR, pA2 ≅ 5.6) and aorta (α1D-AR, pA2 ≅ 5.6), but not in spleen (α1B-AR). The affinities estimated for mirabegron in functional assays were consistent with those estimated in radioligand binding with human recombinant α1A-and α1D-ARs (pKi ≅ 5.6). RT-PCR and immunohistochemistry confirmed the presence of β3-AR in mouse urethra.
Conclusion: The effects of mirabegron in mouse urethra smooth muscle are the result of β3-AR agonism together with α1A / α1D-AR antagonism. The combination of both of these pharmacological actions may contribute to the efficacy of mirabegron in treating OABassociated with BOO.
